Skip to content
Menu

Oppenheimer Reiterates Outperform on Pelthos Therapeutics, Raises Price Target to $57

Benzinga Newsdesk 1 year ago

NewsPrice TargetReiterationAnalyst Ratings

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Oppenheimer analyst Jeff Jones reiterates Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $50 to $57.

Oppenheimer analyst Jeff Jones reiterates Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $50 to $57.

Read at benzinga.com